StreetAlpha.app
Home › Stocks › TVTX

Travere Therapeutics, Inc. (TVTX)

Healthcare
$47.00
▼ −2.69%
LAST CLOSE · NOV 20

Travere Therapeutics is a San Diego biopharmaceutical company that develops and sells treatments for rare kidney and metabolic diseases. It last closed at $47.00 on Nov 20, down 2.69% on the day. The next earnings report for TVTX is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, TVTX reported EPS of -$0.55 on revenue of $224.6M, with revenue up 36.2% from a year ago. Over its last 8 reports the stock moved an average of 7.3% the session after earnings. Over the last 12 months TVTX insiders bought $0 of stock on the open market and sold $110.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is TVTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TVTX.

Key Stats

Last 12 months
Results
Revenue
$651.0M
+49.4% vs a year ago
Net income
−$121.5M
−18.7% margin
EPS (diluted)
−$1.30
Gross margin
98.5%
$641.5M gross profit
Valuation
Market cap
$4.5B
96.0M shares
P/E
–
No P/E while losing money
Price to sales
6.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$123.5M
At Sep 30
Shareholder equity
$22.6M
Shares outstanding
96.0M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $131.8M$131.8MFY2021FY2022: $109.5M$109.5MFY2022FY2023: $145.2M$145.2MFY2023FY2024: $233.2M$233.2MFY2024FY2025: $490.7M$490.7MFY2025

From TVTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
-$0.55
Quarter ended Sep 2026
Year ago EPS
$0.28
−296.4% on a GAAP basis
Revenue
$224.6M
+36.2% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.71Dec '24Mar 2025: -$0.47Mar '25Jun 2025: -$0.14Jun '25Sep 2025: $0.28Sep '25Dec 2025: $0.03Dec '25Mar 2026: -$0.40Mar '26Jun 2026: -$0.37Jun '26Sep 2026: -$0.55Sep '26Latest -$0.55
Revenue by quarter
Dec 2024: $74.8MDec '24Mar 2025: $81.7MMar '25Jun 2025: $114.4MJun '25Sep 2025: $164.9MSep '25Dec 2025: $129.7MDec '25Mar 2026: $127.2MMar '26Jun 2026: $169.6MJun '26Sep 2026: $224.6MSep '26Latest $224.6M
How TVTX moved after its last 8 reports
Average move the session after a report ±7.3%
Nov 2, 2026After the close+0.3%
Aug 4, 2026After the close+12.0%
May 4, 2026After the close−0.2%
Feb 19, 2026After the close+3.7%
Jan 12, 2026After the close−14.6%
Oct 30, 2025After the close+18.6%
Aug 6, 2025After the close−1.9%
Feb 20, 2025After the close−6.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on TVTXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TVTX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TVTX

Technical Analysis

TVTX · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 7% below its 20 day and 15% below its 50 day average. It is 2% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot S1 at $46.15, and the nearest resistance the Pivot at $47.75.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 5.2%/day
Key levels
$68.7352 week high+46.2%
$57.60100 day average+22.6%
$54.2350 day average+15.4%
$50.3220 day average+7.1%
$48.60Pivot R1+3.4%
$48.58Swing high (May 29)+3.4%
$48.13200 day average+2.4%
$47.75Pivot+1.6%
$47.00Last close
$46.15Pivot S1−1.8%
$44.73Swing low (Nov 3)−4.8%
$22.5952 week low−51.9%
Indicators
RSI (14)35.19Weak, oversold below 30Neutral
MACD-1.31Below its signal lineBearish
Stochastic44.1Middle of its rangeNeutral
ADX (14)17.8No clear trend
Williams %R-73.5Oversold below −80, overbought above −20Neutral
CCI (20)-217.2Oversold below −100, overbought above 100Oversold
Rate of change−5.2%Change over 10 sessionsBearish
ATR (14)$2.46Typical daily range, 5.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TVTX

What happened before

See how TVTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow TVTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How TVTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for TVTXHow many large options trades hit TVTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

TVTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲213 buying vs 140 selling
  • ▲Held by funds +6.0 pts
  • ▲Funds holding +26
  • ▼Superinvestors: 1 added, 3 cut
  • ▼Put/call 0.01 to 0.03
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding353327+8.0%
In funds' top 101311+18.2%
Held by funds121.7%115.7%+6.0 pts
New / increased65 / 14893 / 1200.0%
Reduced / sold out103 / 3786 / 31+19.7%
Put/call ratio0.030.01+167.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TVTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TVTX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$110.4M57 sales · 11 insiders
99% of the selling was under pre-arranged trading plans.
2025-12 sold $4.3M2026-01 sold $2.2M2026-02 sold $7.0M2026-03 sold $281K2026-04 sold $11.2M2026-05 sold $4.6M2026-06 sold $726K2026-08 sold $633K2026-09 sold $66.4M2026-10 sold $13.1MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 15Eric M DubeCEOSale plan243,735$53.82$13.1M
Sep 17Eric M DubeCEOSale plan400,000$63.48$25.4M
Sep 17Peter HeermaEvp, Chief Commercial OfficerSale plan283,189$63.06$17.9M
Sep 16William E. RoteChief Research OfficerSale plan209,048$62.83$13.1M
Sep 15Elizabeth E ReedChief Legal Officer and GCSale plan37,500$62.34$2.3M
Sep 15Sandra CalvinSvp, Chief Accounting OfficerSale plan5,375$62.33$335K
Every insider buy and sale for TVTX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TVTX insider trades →

From SEC Form 4 filings by TVTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TVTX is in one of them and how their past TVTX trades turned out.

TVTX in the AI portfolios
Loading…

TVTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TVTX in an article yet. Here's the latest on the wider market.

TVTX in the news

About Travere Therapeutics

Travere Therapeutics is a biopharmaceutical company based in San Diego, California. It develops and sells treatments for people with rare kidney and metabolic diseases. Its approved product, FILSPARI, is indicated to slow kidney function decline in adults with a rare kidney disease called primary IgAN. The company is also seeking approval of FILSPARI for another kidney condition, FSGS, and is developing pegtibatinase for HCU, a genetic metabolic disorder.

Headquarters
San Diego, CA